ClinicalTrials.gg
RecruitingNCT07464912Updated Mar 11, 2026

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 interventional study of TDI01 in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Beijing Tide Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
7th of 60
508 · median 83
Started
2025
with 9 others
Phase 3
13 of 67
5 open now
Primary completion
2029-07
later than 25 of 28 live
Registered
55th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 7th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 25 of the 28 other live ones, and was the 55th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF). The study will be conducted in China and divided into two stages, both of which are multicentre, randomised, double-blind, placebo-controlled studies. Stage 1 aims to evaluate the efficacy and safety of TDI01 suspension compared to the placebo group in the treatment of IPF patients, and Stage 2 aims to further confirm the efficacy and safety of TDI01 suspension compared to the placebo group in the treatment of IPF patients.

Read the detailed description

[Stage 1 study design] Stage 1 is divided into a screening period, a main study treatment period, an extension treatment period, and a safety visit period. Based on a previous Phase 2 study, it is planned to enrol 80 subjects.

All subjects who may participate in this study will enter the screening period (no more than 4 weeks) after voluntarily signing the informed consent form, and the investigator will assess the eligibility of the subjects according to the inclusion and exclusion criteria. All subjects will be re-assessed for eligibility before randomisation, and those who meet the criteria can enter the main study treatment period.

[Stage 2 study design] Stage 2 is divided into a screening period, a main study treatment period, an extension treatment period, and a safety visit period. It is initially planned to enrol 428 subjects, and the target population for both stages is the same.

The inclusion and exclusion criteria and randomisation procedure for the screening period of Stage 2 are the same as those for Stage 1. The main study treatment period is 52 weeks. The dosing regimen and dose adjustment plan for the investigational medicinal product in Stage 2 are the same as those in Stage 1. The proportion of subjects receiving IPF therapeutic drugs shall not be less than 40% of the total number of subjects.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Diagnosed with IPF

    1. Confirmed diagnosis before screening: Diagnosis was made according to the 2022 clinical practice guideline principles of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Society (ALAT) (see Appendix 1), confirmed by the investigators based on chest high-resolution CT (HRCT) performed within 12 months before Visit 1, and surgical lung or transbronchial lung cryobiopsy (if available);
    2. Reconfirmation of IPF diagnosis at screening: And before Visit 2, the independent imaging review panel of experts reviewed and confirmed that the HRCT (HRCT within 3 months before randomisation in the same site was accepted) is consistent with a clinical diagnosis of usual interstitial pneumonia (UIP) or probable UIP for IPF. For subjects with an HRCT finding of "indeterminate for UIP", if a local (previous) surgical lung biopsy or transbronchial lung cryobiopsy has been performed, the pathological slides must be submitted for central review and assessment. If the histopathological features show "UIP" or "probable UIP", the clinical diagnosis of IPF can be confirmed;
  2. Voluntarily participates in this clinical study and signs the form before the start of the study;
  3. Age is 40-80 years (inclusive of 40 and 80 years) at the time of signing the informed consent form, regardless of sex;
  4. Female or male subjects of agree and commit to using highly effective measures (see Appendix 8 in 19.8) from the time of signing the informed consent form until 90 days after the last dose of the medicinal product;
  5. Stable disease for at least 8 weeks prior to Visit 1. Patients must meet one of the following two criteria:

    1. Did not receive treatment with nintedanib and/or pirfenidone for at least 8 weeks prior to Visit 1 (including patients not treated with nintedanib/pirfenidone and those who had failed treatment with nintedanib/pirfenidone);
    2. Or have been receiving a stable* regimen of nintedanib or pirfenidone for at least 12 weeks prior to Visit 1, and plan to continue receiving this background therapy stably after randomisation [*stable treatment is defined as the patient being able to generally tolerate continuous treatment with an unchanged dose of pirfenidone (400 mg TID and above) or nintedanib (100 mg BID and above)];
  6. At screening and baseline, (FEV1)/FVC ratio ≥ 0.70;
  7. At screening and baseline, FVC% of predicted is greater than 50% (inclusive);
  8. DLco (-corrected) percent of predicted normal value is greater than 30% (inclusive) at screening and at baseline;
  9. Active bacterial, viral, parasitic, or fungal infection requiring systemic treatment within 4 weeks prior to screening, but the infection is judged by the investigator to be cured during the screening period;
  10. In the investigator's assessment, the subject is willing and able to comply with protocol requirements and attend visits.

Exclusion Criteria:

Inclusion criteria

Subjects who meet each of the following criteria will be allowed to participate in this study:

  1. Diagnosed with IPF

    1. Confirmed diagnosis before screening: Diagnosis was made according to the 2022 clinical practice guideline principles of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Society (ALAT) (see Appendix 1), confirmed by the investigators based on chest high-resolution CT (HRCT) performed within 12 months before Visit 1, and surgical lung biopsy or transbronchial lung cryobiopsy (if available);
    2. Reconfirmation of IPF diagnosis at screening: And before Visit 2, the independent imaging review panel of experts reviewed and confirmed that the HRCT (HRCT within 3 months before randomisation in the same site was accepted) is consistent with a clinical diagnosis of usual interstitial pneumonia (UIP) or probable UIP for IPF. For subjects with an HRCT finding of "indeterminate for UIP", if a local (previous) surgical lung biopsy or transbronchial lung cryobiopsy has been performed, the pathological slides must be submitted for central review and assessment. If the histopathological features show "UIP" or "probable UIP", the clinical diagnosis of IPF can be confirmed;
  2. Voluntarily participates in this clinical study and signs the informed consent form before the start of the study;
  3. Age is 40-80 years (inclusive of 40 and 80 years) at the time of signing the informed consent form, regardless of sex;
  4. Female or male subjects of childbearing potential agree and commit to using highly effective contraceptive measures (see Appendix 8 in 19.8) from the time of signing the informed consent form until 90 days after the last dose of the investigational medicinal product;
  5. Stable disease for at least 8 weeks prior to Visit 1. Patients must meet one of the following two criteria:

    1. Did not receive treatment with nintedanib and/or pirfenidone for at least 8 weeks prior to Visit 1 (including patients not treated with nintedanib/pirfenidone and those who had failed treatment with nintedanib/pirfenidone);
    2. Or have been receiving a stable* regimen of nintedanib or pirfenidone for at least 12 weeks prior to Visit 1, and plan to continue receiving this background therapy stably after randomisation [*stable treatment is defined as the patient being able to generally tolerate continuous treatment with an unchanged dose of pirfenidone (400 mg TID and above) or nintedanib (100 mg BID and above)];
  6. At screening and baseline, forced expiratory volume in one second (FEV1)/FVC ratio ≥ 0.70;
  7. At screening and baseline, FVC% of predicted is greater than 50% (inclusive);
  8. DLco (Hb-corrected) percent of predicted normal value is greater than 30% (inclusive) at screening and at baseline;
  9. Active bacterial, viral, parasitic, or fungal infection requiring systemic treatment within 4 weeks prior to screening, but the infection is judged by the investigator to be cured during the screening period;
  10. In the investigator's assessment, the subject is willing and able to comply with protocol requirements and attend visits.

Exclusion criteria

Subjects who meet any of the following criteria will not be allowed to participate in this study:

  1. Other known causes of interstitial lung disease, such as home or occupational environmental exposure, connective tissue disease, drugs, etc.;
  2. With other lung diseases besides IPF (such as asthma, or significant airways obstruction [FEV1/FVC ratio \<0.7], pneumonitis, eosinophilic pneumonia, etc.);
  3. Patients who are planning to undergo a lung transplant within 12 months after screening;
  4. Active infection tuberculosis within 12 months prior to screening, or any active bacterial, viral, parasitic, or fungal infection requiring systemic treatment during the screening period;
  5. Subjects whose IPF condition is assessed by the investigator as unstable at screening, or who have had an acute exacerbation of IPF within 8 weeks before screening and/or during the screening period;
  6. Use of any of the following treatments within 4 weeks prior to randomisation:

    1. IPF therapeutic drugs, unstable treatment with nintedanib or pirfenidone, > 15 mg/d prednisone or equivalent doses of other , use of immunomodulatory drugs other than glucocorticoids for respiratory/pulmonary reasons; [Stable treatment is defined as the individual patient being able to generally tolerate continuous treatment with an unchanged dose of pirfenidone (400 mg TID and above) or nintedanib (100 mg BID and above) for at least 8 weeks];
    2. Strong inhibitors (including but not limited to ritonavir, clarithromycin, idelalisib, etc., see Appendix 4 for details);
    3. Narrow therapeutic window substrates of CYP2C9 (such as warfarin, tolbutamide, and phenytoin) and sensitive substrates of P-gp (such as digoxin);
    4. ROCK2 inhibitor (belumosudil);
  7. History of malignant tumour within 5 years prior to screening (except for patients with appropriately treated skin basal cell carcinoma or squamous cell carcinoma of skin in situ or in situ cancer of cervix);
  8. Moderate to severe hepatic insufficiency ( Class B or C) before screening;
  9. Laboratory test results exceeding any of the following criteria at screening and at baseline: total >1.5× or /ALT>2×ULN, serum CK>1.5×ULN;
  10. Uncontrolled virus infection (HBsAg positive and HBV-DNA ≥ 102 IU/mL) or virus infection (anti-HCV and HCV-RNA positive) at screening;
  11. With history of unstable or worsening cardiac disorder within 6 months prior to screening, including but not limited to the following:

    1. Unstable angina;
    2. Myocardial infarction;
    3. CCF requiring hospitalisation or Class III/IV;
    4. Uncontrolled severe arrhythmia.
  12. Family history of long syndrome or sudden death, or clinically significant abnormalities on at screening and baseline, including but not limited to: QTcF interval > 470 ms (female) or >450 ms (male), fibrillation atrial or flutter atrial, second-degree or third-degree AV block, left bundle branch block;
  13. SBP >160 mmHg or DBP >100 mmHg at screening and baseline (to be measured after at least 5 minutes of rest, and confirmed by one re-check to still meet this standard);
  14. Cerebrovascular event leading to hospitalisation within 12 months prior to screening, including but not limited to hematencephalon, subarachnoid haemorrhage, stroke, etc.;
  15. (CLcr) \<50 mL/min at screening and baseline, calculated using the Cockcroft-Gault formula: [140 - age (years)] [weight (kg)] × (0.85, if female) / [72 × blood creatinine (mg/dL)];
  16. Unable to complete the six minute walk distance (6MWD) or pulmonary function test (PFT);
  17. History of smoking within 3 months prior to screening or unwillingness to practice cessation of smoking during the study;
  18. Frequent alcohol use [more than 21 units of alcohol per week (1 unit = 360 mL beer or 45 mL of 40% alcohol or 150 mL wine)] within 6 months before screening, or unwillingness to reduce alcohol intake to within 21 units during the study;
  19. History of drug abuse within 6 months prior to screening;
  20. Pregnancy or lactation;
  21. (HIV) antibody test result is non-negative at screening;
  22. Allergy to any component of TDI01 suspension;
  23. The last dose in other clinical studies was administered within 3 months or 5 half-lives prior to screening, whichever is longer;
  24. Major surgery (general anaesthesia surgery) within 3 months prior to screening, or planned surgery during the study period that is considered by the investigator to affect the judgment of study endpoints;
  25. The investigator assesses that the subject has an unstable state of other systemic or organ diseases, which may impair their safety or compliance, affect drug absorption, or lead to other conditions that prevent them from completing the study assessments.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
508 participants (estimated)

Study arms

  • Experimental
    TDI01 400 mg

    400 mg, once daily, shake well before administration, orally on an empty stomach

    Drug: TDI01

  • Placebo comparator
    Placebo

    Once daily, shake well before administration, orally on an empty stomach

    Drug: TDI01

Interventions

  • DrugTDI01

    TDI01 suspension

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Absolute change in forced vital capacity (FVC) (mL) from baseline at Week 24 and week 52.

    Time frame: Week 24, Week 52.

Secondary outcomes

  1. Secondary efficacy endpoints:

    Absolute change in FVC (mL) from baseline at Weeks 6 and 12.

    Time frame: Week 6 ,Week 12

  2. Secondary Outcome Measure

    Time (days) to the first occurrence of ppFVC% absolute decline \>10%, acute exacerbation of IPF (AE-IPF), hospitalisation due to respiratory causes, or death due to respiratory causes (whichever occurs first) during the trial period;

    Time frame: Week 24, Week 52

  3. Secondary Outcome Measure

    Absolute change from baseline in FVC percent predicted (ppFVC%), six minute walk distance (6MWD), St. George's Respiratory Questionnaire (SGRQ) score, and carbon monoxide diffusing capacity (DLco%) (Hb-corrected) at Week 24 and 52.

    Time frame: Week 24, Week 52

  4. Secondary Outcome Measure

    Time (days) to a 10% absolute decline in ppFVC%;

    Time frame: Week 24, Week 52

  5. Secondary Outcome Measure

    Time (days) to a 15% absolute decline in DLco%;

    Time frame: Week 24, Week 52

  6. Secondary Outcome Measure

    Time (days) to the first occurrence of acute exacerbation of IPF;

    Time frame: week 24, week 52

  7. Secondary Outcome Measure

    Time (days) to IPF-related death or all-cause death.

    Time frame: week 24, week 52

  8. Safety endpoints:

    Adverse event assessment and other safety indicator evaluations (including high-resolution CT, laboratory tests, 12-lead ECG, vital signs, physical examination, etc.).

    Time frame: week 24, week 52

Other outcomes

  1. Exploratory endpoints:

    Thoracic imaging progression on HRCT, such as new ground-glass opacity with traction bronchiectasis, new fine reticular pattern, increased extent or severity of coarse reticular pattern, new honeycombing, or worsening of existing honeycombing.

    Time frame: Week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2029, 43 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Mar 11, 2026
StartActual
Dec 24, 2025
Primary completionEst.
Jul 30, 2029
CompletionEst.
Dec 30, 2029
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07464912
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Dec 24, 2025
Primary completion
Jul 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Mar 11, 2026

Study contacts

HuaPing Dai, Dr.
Contact
daihuaping@ccmu.edu.cn
8610-84206278

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TDI01

Start the discussion